Buy Full Version
"Genetic Testing Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Genetic Testing Market by Type (Predictive Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), and Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Diagnostics and Biotech	LI_195241	Pages: 246	Apr 2019 \| 4304 Views
Author(s) : Surabhi Pandey and Tenzin Kunsel	Tables: 121	Charts: 53	Formats*:

Genetic Testing Market Outlook - 2025

The global genetic testing market was valued at $7,502 million in 2017 and is projected to reach $17,607 million by 2025, growing at a CAGR of 11.3% from 2018 to 2025.

Genetic testing is the study of gene present in cells and tissues. This study is further applied in the field of biology and medicine to better understand genetic disorders such as cancer, sickle cell anemia, cystic fibrosis, Down syndrome, and others. The scope of the report discusses the use of gene tests for the development of personalized medicine, targeted cancer treatment, and other genetic diseases. Moreover, it highlights a wide range of techniques such as cytogenetic testing/chromosome analysis, biochemical testing, molecular testing, and DNA sequencing, which includes comparative genomic hybridization, fluorescence in situ hybridization, karyotyping, and others that are employed for the screening of genetic abnormalities and cancers. These techniques employ the use of gene tests products such as kits, media, reagents, and others.

Get more information on this report : Request Sample Pages

The global genetic testing market is expected to register substantial growth in the near future due to rise in incidence of genetic disorders & cancer and growth in awareness & acceptance of personalized medicines. In addition, advancements in genetic testing techniques and increasing application of genetic testing in oncology are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the genetic testing market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players. Therefore, these factors are anticipated to boost the global genetic testing market share.

The global genetic testing market is segmented based on type, technology, application, and region. By type, the market is categorized into predictive testing, predictive testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, the market is divided into cytogenetic testing, DNA sequencing, molecular testing, and DNA sequencing. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get more information on this report : Request Sample Pages

Type segment review

Based on type, the market is segmented into predictive testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. The diagnostic testing segment currently holds the lead with revenue in 2017 and is expected to maintain its dominance during the forecast period. This is attributable to the growth in awareness among people regarding health and increase in incidences of mortality rate due to the genetic diseases across the world. On the other hand, the pharmacogenomic testing segment is anticipated to witness highest CAGR during the forecast period. This is largely due to increase in application of drug discovery and development by the pharmaceutical companies.

Get more information on this report : Request Sample Pages

Application segment review

Depending on application, the genetic testing market is categorized into chromosome analysis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. The cardiovascular diseases diagnosis segment is projected to exhibit the highest growth during the forecast period. This is attributed to the increasing rate of mortality due to the inherited heart diseases that are caused by one or very few genetic changes and that causes heart diseases including inherited cardiomyopathies, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and others. Thus, it helps in increasing the genetic testing market size in the near future.

Get more information on this report : Request Sample Pages

Region segment review

Based on geography, the genetic testing market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the leading revenue contributor to the global genetic testing market in 2017 and is expected to dominate the market during the forecast period. This is attributed to the presence of majority of key players in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness toward early screening of genetic disorders.

The report provides a comprehensive analysis of the key players operating in the global genetic testing market, which include Abbott Laboratories, Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Novartis International AG, and Thermo Fisher Scientific, Inc. The other players in the genetic testing industry include Agilent Technologies, Inc., Empire Genomics, LLC, Irvine Scientific, PerkinElmer, Inc., Sysmex Corporation, and others.

Key Benefits for Genetic Testing Market:

This report provides a detailed quantitative analysis of the current genetic testing market trends and genetic testing market forecast estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth genetic testing market analysis includes analysis of various regions and is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global market is provided.
Region-wise and country-wise market conditions are comprehensively analyzed in this report.
The projections in this report are made by analyzing the current trends and future market potential from 2018 to 2025 in terms of value.
An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
Key market players within the genetic testing market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the global genetic testing market.

Genetic Testing Key Market Segments:

By Type

Predictive Testing
Carrier Testing
Prenatal & Newborn Testing
Diagnostic Testing
Pharmacogenomic Testing
Others

By Technology

Cytogenetic Testing/ Chromosome Analysis
Biochemical Testing
Molecular Testing
- DNA Sequencing
- Others

By Application

Chromosome Analysis
Genetic Disease Diagnosis
Cardiovascular Disease Diagnosis
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Australia
- Japan
- India
- China
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

CHAPTER 1: INTRODUCTION

1.1.   Report description
1.2.   Key benefits for stakeholders
1.3.   Key market segments
1.4.   Research methodology

1.4.1.   Secondary research
1.4.2.   Primary research
1.4.3.   Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3.   Porter’s five forces analysis
3.4.   Top Player Positioning, 2017
3.5.   Market dynamics

3.5.1. Drivers

3.5.1.1.   Increase in incidence of genetic disorders & cancer
3.5.1.2.   Rise in awareness & acceptance of personalized medicines
3.5.1.3.   Advancements in genetic testing techniques

3.5.2. Restraint

3.5.2.1. Standardization concerns of genetic testing-based diagnostics
3.5.2.2. Stringent regulatory requirements for product approvals

3.5.3. Opportunities

3.5.3.1. Untapped emerging markets in developing countries

3.6. Patent analysis (2015-2018)

3.6.1. Patent analysis, by year
3.6.2. Patent analysis for year 2017, by country

CHAPTER 4: GENETIC TESTING MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Predictive and presymptomatic testing

4.2.1.   Key trends and opportunities
4.2.2.   Market size and forecast
4.2.3.   Market analysis, by country

4.3. Carrier testing

4.3.1.   Key market trends and opportunities
4.3.2.   Market size and forecast
4.3.3.   Market analysis, by country

4.4. Prenatal and newborn testing

4.4.1.   Key market trends and opportunities
4.4.2.   Market size and forecast
4.4.3.   Market analysis, by country

4.5. Diagnostic testing

4.5.1.   Key market trends and opportunities
4.5.2.   Market size and forecast
4.5.3.   Market analysis, by country

4.6. Pharmacogenomic testing

4.6.1.   Key trends and opportunities
4.6.2.   Market size and forecast
4.6.3.   Market analysis, by country

4.7. Others

4.7.1.   Key trends and opportunities
4.7.2.   Market size and forecast
4.7.3.   Market analysis, by country

CHAPTER 5: GENETIC TESTING MARKET, BY TECHNOLOGY

5.1. Overview

5.1.1. Market size and forecast

5.2. Cytogenetic testing/chromosome analysis

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Biochemical testing

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Molecular testing

5.4.1. Market size and forecast, by type
5.4.2. DNA Sequencing

5.4.2.1. Market size and forecast, by region

5.4.3. Others

5.4.3.1. Market size and forecast, by region

5.4.4. Market size and forecast
5.4.5. Market analysis, by country

CHAPTER 6: GENETIC TESTING MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Cancer diagnosis

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Genetic disease diagnosis

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

6.4. Cardiovascular disease diagnosis

6.4.1. Market size and forecast
6.4.2. Market analysis, by country

6.5. Others

6.5.1. Market size and forecast
6.5.2. Market analysis, by country

CHAPTER 7: GENETIC TESTING MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1.   Key market trends and opportunities
7.2.2.   Market size and forecast, by test type
7.2.3.   Market size and forecast, by technology
7.2.4.   Market size and forecast, by application
7.2.5.   Market size and forecast, by country

7.2.5.1.   U.S. market size and forecast, by test type
7.2.5.2.   U.S. market size and forecast, by technology
7.2.5.3.   U.S. market size and forecast, by application
7.2.5.4.   Canada market size and forecast, by test type
7.2.5.5.   Canada market size and forecast, by technology
7.2.5.6.   Canada market size and forecast, by application
7.2.5.7.   Mexico market size and forecast, by test type
7.2.5.8.   Mexico market size and forecast, by technology
7.2.5.9.   Mexico market size and forecast, by application

7.3. Europe

7.3.1.   Key market trends, growth factors, and opportunities
7.3.2.   Market size and forecast, by test type
7.3.3.   Market size and forecast, by technology
7.3.4.   Market size and forecast, by application
7.3.5.   Market size and forecast, by country

7.3.5.1.   Germany market size and forecast, by test type
7.3.5.2.   Germany market size and forecast, by technology
7.3.5.3.   Germany market size and forecast, by application
7.3.5.4.   France market size and forecast, by test type
7.3.5.5.   France market size and forecast, by technology
7.3.5.6.   France market size and forecast, by application
7.3.5.7.   UK market size and forecast, by test type
7.3.5.8.   UK market size and forecast, by technology
7.3.5.9.   UK market size and forecast, by application
7.3.5.10.   Italy market size and forecast, by test type
7.3.5.11.   Italy market size and forecast, by technology
7.3.5.12.   Italy market size and forecast, by application
7.3.5.13.   Spain market size and forecast, by test type
7.3.5.14.   Spain market size and forecast, by technology
7.3.5.15.   Spain market size and forecast, by application
7.3.5.16.   rest of Europe market size and forecast, by test type
7.3.5.17.   rest of Europe market size and forecast, by technology
7.3.5.18.   Rest of Europe market size and forecast, by application

7.4. Asia-Pacific

7.4.1.   Key market trends, growth factors, and opportunities
7.4.2.   Market size and forecast, by test type
7.4.3.   Market size and forecast, by technology
7.4.4.   Market size and forecast, by application
7.4.5.   Market size and forecast, by country

7.4.5.1.   Japan market size and forecast, by test type
7.4.5.2.   Japan market size and forecast, by technology
7.4.5.3.   Japan market size and forecast, by application
7.4.5.4.   China market size and forecast, by test type
7.4.5.5.   China market size and forecast, by technology
7.4.5.6.   China market size and forecast, by application
7.4.5.7.   Australia market size and forecast, by test type
7.4.5.8.   Australia market size and forecast, by technology
7.4.5.9.   Australia market size and forecast, by application
7.4.5.10.   India market size and forecast, by test type
7.4.5.11.   India market size and forecast, by technology
7.4.5.12.   India market size and forecast, by application
7.4.5.13.   South Korea market size and forecast, by test type
7.4.5.14.   South Korea market size and forecast, by technology
7.4.5.15.   South Korea market size and forecast, by application
7.4.5.16.   Rest of Asia-Pacific market size and forecast, by test type
7.4.5.17.   Rest of Asia-Pacific market size and forecast, by technology
7.4.5.18.   Rest of Asia-Pacific market size and forecast, by application

7.5. LAMEA

7.5.1.   Key market trends, growth factors, and opportunities
7.5.2.   Market size and forecast, by test type
7.5.3.   Market size and forecast, by technology
7.5.4.   Market size and forecast, by application
7.5.5.   Market size and forecast, by country

7.5.5.1.   Brazil market size and forecast, by test type
7.5.5.2.   Brazil market size and forecast, by technology
7.5.5.3.   Brazil market size and forecast, by application
7.5.5.4.   Saudi Arabia market size and forecast, by test type
7.5.5.5.   Saudi Arabia market size and forecast, by technology
7.5.5.6.   Saudi Arabia market size and forecast, by application
7.5.5.7.   South Africa market size and forecast, by test type
7.5.5.8.   South Africa market size and forecast, by technology
7.5.5.9.   South Africa market size and forecast, by application
7.5.5.10.   Rest of LAMEA market size and forecast, by test type
7.5.5.11.   Rest of LAMEA market size and forecast, by technology
7.5.5.12.   Rest of LAMEA market size and forecast, by application

CHAPTER 8: COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1.   Company overview
8.1.2.   Company snapshot
8.1.3.   Operating business segments
8.1.4.   Product portfolio
8.1.5.   Business performance

8.2. BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.)

8.2.1.   Company overview
8.2.2.   Company snapshot
8.2.3.   Operating business segments
8.2.4.   Product portfolio
8.2.5.   Business performance
8.2.6.   Key strategic moves and developments

8.3. DANAHER CORPORATION (CEPHEID)

8.3.1.   Company overview
8.3.2.   Company snapshot
8.3.3.   Operating business segments
8.3.4.   Product portfolio
8.3.5.   Business performance
8.3.6.   Key strategic moves and developments

8.4. EUROFINS SCIENTIFIC

8.4.1.   Company overview
8.4.2.   Company snapshot
8.4.3.   Product portfolio
8.4.4.   Business performance
8.4.5.   Key strategic moves and developments

8.5. F. HOFFMANN-LA ROCHE LTD.

8.5.1.   Company overview
8.5.2.   Company snapshot
8.5.3.   Operating business segments
8.5.4.   Product portfolio
8.5.5.   Business performance
8.5.6.   Key strategic moves and developments

8.6. ILLUMINA, INC.

8.6.1.   Company overview
8.6.2.   Company snapshot
8.6.3.   Operating business segments
8.6.4.   Product portfolio
8.6.5.   Business performance

8.7. MYRIAD GENETICS, INC. (MYRIAD RBM, INC.)

8.7.1.   Company overview
8.7.2.   Company snapshot
8.7.3.   Operating business segments
8.7.4.   Product portfolio
8.7.5.   Business performance

8.8. NOVARTIS INTERNATIONAL AG

8.8.1.   Company overview
8.8.2.   Company snapshot
8.8.3.   Operating business segments
8.8.4.   Product portfolio
8.8.5.   Business performance

8.9. QIAGEN N.V. (FORMULATRIX, INC.)

8.9.1.   Company overview
8.9.2.   Company snapshot
8.9.3.   Product portfolio
8.9.4.   Business performance
8.9.5.   Key strategic moves and developments

8.10. THERMO FISHER SCIENTIFIC, INC.

8.10.1.   Company overview
8.10.2.   Company snapshot
8.10.3.   Operating business segments
8.10.4.   Product portfolio
8.10.5.   Business performance

LIST OF TABLES

TABLE 01.   GLOBAL GENETIC TESTING MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 02.   GLOBAL GENETIC TESTING MARKET FOR PREDICTIVE AND PRESYMPTOMATIC TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 03.   GLOBAL GENETIC TESTING MARKET FOR CARRIER TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 04.   GLOBAL GENETIC TESTING MARKET FOR PRENATAL AND NEWBORN TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 05.   GLOBAL GENETIC TESTING MARKET FOR DIAGNOSTIC TESTING BY REGION, 2017–2025 ($MILLION)
TABLE 06.   GLOBAL GENETIC TESTING MARKET FOR PHARMACOGENOMIC TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 07.   GLOBAL GENETIC TESTING MARKET FOR OTHER TYPES, BY REGION, 2017–2025 ($MILLION)
TABLE 08.   GLOBAL GENETIC TESTING MARKET, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 09.   GENETIC TESTING MARKET FOR CYTOGENETIC TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 10.   GENETIC TESTING MARKET FOR BIOCHEMICAL TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 11.   GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY TYPE, 2017–2025 ($MILLION)
TABLE 12.   GENETIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2017–2025 ($MILLION)
TABLE 13.   GENETIC TESTING MARKET FOR OTHER MOLECULAR TESTS, BY REGION, 2017–2025 ($MILLION)
TABLE 14.   GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY REGION, 2017–2025 ($MILLION)
TABLE 15.   GLOBAL GENETIC TESTING MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 16.   GLOBAL GENETIC TESTING MARKET FOR CANCER DIAGNOSIS, BY REGION, 2017–2025 ($MILLION)
TABLE 17.   GLOBAL GENETIC TESTING MARKET FOR GENETIC DISEASE DIAGNOSIS, BY REGION, 2017–2025 ($MILLION)
TABLE 18.   GLOBAL GENETIC TESTING MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2017–2025 ($MILLION)
TABLE 19.   GLOBAL GENETIC TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2025 ($MILLION)
TABLE 20.   GENETIC TESTING MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)
TABLE 21.   NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 22.   NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 23.   NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 24.   NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 25.   U.S. GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 26.   U.S. GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 27.   U.S. GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 28.   CANADA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 29.   CANADA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 30.   CANADA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 31.   MEXICO GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 32.   MEXICO GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 33.   MEXICO GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 34.   EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 35.   EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 36.   EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 37.   EUROPE GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 38.   GERMANY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 39.   GERMANY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 40.   GERMANY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 41.   FRANCE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 42.   FRANCE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 43.   FRANCE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 44.   UK GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 45.   UK GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 46.   UK GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 47.   ITALY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 48.   ITALY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 49.   ITALY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 50.   SPAIN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 51.   SPAIN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 52.   SPAIN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 53.   REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 54.   REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 55.   REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 56.   ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 57.   ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 58.   ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 59.   ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 60.   JAPAN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 61.   JAPAN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 62.   JAPAN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 63.   CHINA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 64.   CHINA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 65.   CHINA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 66.   AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 67.   AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 68.   AUSTRALIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 69.   INDIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 70.   INDIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 71.   INDIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 72.   SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 73.   SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 74.   SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 75.   REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 76.   REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 77.   REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 78.   LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 79.   LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 80.   LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 81.   LAMEA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 82.   BRAZIL GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 83.   BRAZIL GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 84.   BRAZIL GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 85.   SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 86.   SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 87.   SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 88.   SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 89.   SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 90.   SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 91.   REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2017–2025 ($MILLION)
TABLE 92.   REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2017–2025 ($MILLION)
TABLE 93.   REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 94.   ABBOTT: COMPANY SNAPSHOT
TABLE 95.   ABBOTT: OPERATING SEGMENTS
TABLE 96.   ABBOTT: PRODUCT PORTFOLIO
TABLE 97.   BIO-RAD: COMPANY SNAPSHOT
TABLE 98.   BIO-RAD: OPERATING SEGMENTS
TABLE 99.   BIO-RAD: PRODUCT PORTFOLIO
TABLE 100.   DANAHER: COMPANY SNAPSHOT
TABLE 101.   DANAHER: OPERATING SEGMENTS
TABLE 102.   DANAHER: PRODUCT PORTFOLIO
TABLE 103.   EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 104.   EUROFINS SCIENTIFIC.: PRODUCT PORTFOLIO
TABLE 105.   ROCHE: COMPANY SNAPSHOT
TABLE 106.   ROCHE: OPERATING SEGMENTS
TABLE 107.   ROCHE: PRODUCT PORTFOLIO
TABLE 108.   ILLUMINA: COMPANY SNAPSHOT
TABLE 109.   ILLUMINA: OPERATING SEGMENTS
TABLE 110.   ILLUMINA: PRODUCT PORTFOLIO
TABLE 111.   MYRIAD: COMPANY SNAPSHOT
TABLE 112.   MYRIAD: OPERATING SEGMENTS
TABLE 113.   MYRIAD: PRODUCT PORTFOLIO
TABLE 114.   NOVARTIS AG: COMPANY SNAPSHOT
TABLE 115.   NOVARTIS: OPERATING SEGMENTS
TABLE 116.   NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 117.   QIAGEN: COMPANY SNAPSHOT
TABLE 118.   QIAGEN: PRODUCT PORTFOLIO
TABLE 119.   THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 120.   THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 121.   THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.   SEGMENTATION OF GENETIC TESTING MARKET
FIGURE 02.   TOP INVESTMENT POCKETS, 2017
FIGURE 03.   MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.   HIGH BARGAINING POWER OF BUYERS
FIGURE 05.   LOW THREAT OF SUBSTITUTION
FIGURE 06.   MODERATE THREAT OF NEW ENTRANT
FIGURE 07.   HIGH COMPETITIVE RIVALRY
FIGURE 08.   GLOBAL GENETIC TESTING TOP PLAYER POSITIONING, 2017
FIGURE 09.   GLOBAL GENETIC TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 10.   PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018
FIGURE 11.   PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018
FIGURE 12.   YEAR 2017 PATENT ANALYSIS, BY COUNTRY
FIGURE 13.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR PREDICTIVE AND PRESYMPTOMATIC TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 14.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR CARRIER TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 15.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR PRENATAL AND NEWBORN TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR DIAGNOSTIC TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR OTHER TYPES, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR CYTOGENETIC TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 20.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR BIOCHEMICAL TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 21.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY COUNTRY, 2017 & 2025 (%)
FIGURE 22.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR CANCER DIAGNOSIS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 23.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR GENETIC DISEASE DIAGNOSIS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 24.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSIS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 25.   COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 26.   ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.   ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.   ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 29.   BIO-RAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 30.   BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31.   BIO-RAD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 32.   DANAHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.   DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.   DANAHER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 35.   EUROFINS SCIENTIFIC.: REVENUE, 2015–2017 ($MILLION)
FIGURE 36.   EUROFINS SCIENTIFIC: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 37.   ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 38.   ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39.   ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40.   ILLUMINA: NET SALES, 2015–2017 ($MILLION)
FIGURE 41.   ILLUMINA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 42.   ILLUMINA: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 43.   MYRIAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 44.   MYRIAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45.   NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 46.   NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47.   NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48.   QIAGEN: NET SALES, 2015–2017 ($MILLION)
FIGURE 49.   QIAGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 50.   QIAGEN: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 51.   THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 52.   THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 53.   THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2018 (%)

The application of genetic testing is anticipated to witness a significant rise with technological advancements, rise in prevalence of cancer & genetic diseases, and increase in awareness & acceptance of personalized medicines for the treatment.

Furthermore, increase in economic strength of the developing nations such as Japan, China, India, Indonesia, Thailand, and others as well as rise in healthcare expenditure are expected to drive the market growth during the forecast period.

Rapid growth was observed in the adoption of advanced technology in the healthcare industry across developing economies, and this is expected to offset the challenging conditions in mature markets such as North America and Europe. Moreover, North America and Europe are expected to dominate the market during the forecast period, while emerging countries in Asia-Pacific and Latin America are expected to offer significant growth opportunities.